Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
2003 1
2004 1
2006 1
2007 2
2008 1
2010 1
2012 1
2018 3
2019 2
2020 3
2021 3
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial.
Maltais F, Bjermer L, Kerwin EM, Jones PW, Watkins ML, Tombs L, Naya IP, Boucot IH, Lipson DA, Compton C, Vahdati-Bolouri M, Vogelmeier CF. Maltais F, et al. Among authors: naya ip. Respir Res. 2019 Oct 30;20(1):238. doi: 10.1186/s12931-019-1193-9. Respir Res. 2019. PMID: 31666084 Free PMC article. Clinical Trial.
Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis.
Han MK, Criner GJ, Dransfield MT, Halpin DMG, Jones CE, Kilbride S, Lange P, Lettis S, Lipson DA, Lomas DA, Martin N, Martinez FJ, Wise RA, Naya IP, Singh D. Han MK, et al. Among authors: naya ip. ERJ Open Res. 2021 Mar 8;7(1):00663-2020. doi: 10.1183/23120541.00663-2020. eCollection 2021 Jan. ERJ Open Res. 2021. PMID: 33718490 Free PMC article.
Treatment of COPD with Long-Acting Bronchodilators: Association Between Early and Longer-Term Clinically Important Improvement.
Vogelmeier CF, Naya IP, Maltais F, Bjermer L, Kerwin EM, Tombs L, Jones PW, Compton C, Lipson DA, Boucot IH. Vogelmeier CF, et al. Among authors: naya ip. Int J Chron Obstruct Pulmon Dis. 2021 May 3;16:1215-1226. doi: 10.2147/COPD.S295835. eCollection 2021. Int J Chron Obstruct Pulmon Dis. 2021. PMID: 33976543 Free PMC article. Clinical Trial.
Dual Bronchodilator Therapy as First-Line Treatment in Maintenance-Naïve Patients with Symptomatic COPD: A Pre-Specified Analysis of the EMAX Trial.
Bjermer L, Boucot IH, Maltais F, Kerwin EM, Naya IP, Tombs L, Jones PW, Compton C, Lipson DA, Vogelmeier CF. Bjermer L, et al. Among authors: naya ip. Int J Chron Obstruct Pulmon Dis. 2021 Jun 28;16:1939-1956. doi: 10.2147/COPD.S291751. eCollection 2021. Int J Chron Obstruct Pulmon Dis. 2021. PMID: 34234425 Free PMC article.
Impact of baseline COPD symptom severity on the benefit from dual versus mono-bronchodilators: an analysis of the EMAX randomised controlled trial.
Vogelmeier CF, Kerwin EM, Bjermer LH, Tombs L, Jones PW, Boucot IH, Naya IP, Lipson DA, Compton C, Barnes N, Maltais F. Vogelmeier CF, et al. Among authors: naya ip. Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620968500. doi: 10.1177/1753466620968500. Ther Adv Respir Dis. 2020. PMID: 33167780 Free PMC article. Clinical Trial.
Early and sustained symptom improvement with umeclidinium/vilanterol versus monotherapy in COPD: a post hoc analysis of the EMAX randomised controlled trial.
Kerwin EM, Boucot IH, Vogelmeier CF, Maltais F, Naya IP, Tombs L, Jones PW, Lipson DA, Keeley T, Bjermer L. Kerwin EM, et al. Among authors: naya ip. Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620926949. doi: 10.1177/1753466620926949. Ther Adv Respir Dis. 2020. PMID: 32462979 Free PMC article. Clinical Trial.
21 results